Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: "Athersys, Inc." (ATHX) Report Updated: Oct 17, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"Athersys, Inc." (ATHX)

Rating: Strong Buy Volatility: Moderate
Total Grade: A Industry: Biotechnology

Stock Analysis

Rating: Monthly View

October November December January February March April May June July August September

Rating: Weekly View

This Week: A down no change
Last Week: A same upgrade
Two Weeks Ago: B up no change
service keys

"Athersys, Inc."© quotemedia

Company Profile

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. The company’s lead platform product, MultiStem cell therapy, an allogeneic stem cell product, which is in Phase II clinical trials for the treatment of ischemic stroke and inflammatory bowel disease (IBD); and that has completed Phase I clinical trial for the treatment of acute myocardial infarction and hematopoietic stem cell transplant/graft-versus-host disease. It is also developing MultiStem cell therapy for the treatment of acute respiratory distress syndrome. Its clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. In addition, the company is involved in identifying and developing small molecule compounds with potential applications in indications, including obesity; related metabolic conditions, such as diabetes; and neurological indications consisting of schizophrenia. It has license agreement with Chugai Pharmaceutical Co., Ltd. to develop MultiStem cell therapy for ischemic stroke in Japan, as well as collaboration agreement with Pfizer Inc. to develop and commercialize MultiStem to treat IBD; and RTI Biologics, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; and collaboration with Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets produced compound screening and development. The company was founded in 1995 and is headquartered in Cleveland, Ohio.